// App-Quantinova.ai

3032 : A novel compound ARN-3236 inhibits SIK2 and sensitizes ovarian cancer to paclitaxel

Researchers

Presenter

  • Jinhua Zhou

Principal Investigators

  • Albandri Alfredi

  • Shu Zhang

  • Janice M. Santiago-OFarrill

  • Ahmed A. Ahmed

  • Hailing Yang

  • Weiqun Mao

  • Yan Wang

  • Hariprasad Vankayalapati

  • Zhen Lu

  • Robert C. Bast

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • University of Oxford, Oxford, United Kingdom

  • Arrien Pharmaceuticals, Salt Lake City, UT.

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ovarian cancer

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Paclitaxel

  • ARN-3236

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved